Literature DB >> 24687046

Impaired metabolic reactivity to oxidative stress in early psychosis patients.

Margot Fournier1, Carina Ferrari2, Philipp S Baumann2, Andrea Polari2, Aline Monin1, Tanja Bellier-Teichmann1, Jacob Wulff3, Kirk L Pappan3, Michel Cuenod1, Philippe Conus4, Kim Q Do5.   

Abstract

Because increasing evidence point to the convergence of environmental and genetic risk factors to drive redox dysregulation in schizophrenia, we aim to clarify whether the metabolic anomalies associated with early psychosis reflect an adaptation to oxidative stress. Metabolomic profiling was performed to characterize the response to oxidative stress in fibroblasts from control individuals (n = 20) and early psychosis patients (n = 30), and in all, 282 metabolites were identified. In addition to the expected redox/antioxidant response, oxidative stress induced a decrease of lysolipid levels in fibroblasts from healthy controls that were largely muted in fibroblasts from patients. Most notably, fibroblasts from patients showed disrupted extracellular matrix- and arginine-related metabolism after oxidative stress, indicating impairments beyond the redox system. Plasma membrane and extracellular matrix, 2 regulators of neuronal activity and plasticity, appeared as particularly susceptible to oxidative stress and thus provide novel mechanistic insights for pathophysiological understanding of early stages of psychosis. Statistically, antipsychotic medication at the time of biopsy was not accounting for these anomalies in the metabolism of patients' fibroblasts, indicating that they might be intrinsic to the disease. Although these results are preliminary and should be confirmed in a larger group of patients, they nevertheless indicate that the metabolic signature of reactivity to oxidative stress may provide reliable early markers of psychosis. Developing protective measures aimed at normalizing the disrupted pathways should prevent the pathological consequences of environmental stressors.
© The Author 2014. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  arginine; extracellular matrix; glutathione; mental disorder; metabolism; phospholipid

Mesh:

Year:  2014        PMID: 24687046      PMCID: PMC4133680          DOI: 10.1093/schbul/sbu053

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  76 in total

1.  Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test.

Authors:  Mariana P Zeidan; Andréa D E Zomkowski; Angelo O Rosa; Ana Lúcia S Rodrigues; Nelson H Gabilan
Journal:  Eur J Pharmacol       Date:  2007-03-24       Impact factor: 4.432

2.  Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia.

Authors:  René Gysin; Rudolf Kraftsik; Olivier Boulat; Pierre Bovet; Philippe Conus; Emily Comte-Krieger; Andrea Polari; Pascal Steullet; Martin Preisig; Tanja Teichmann; Michel Cuénod; Kim Q Do
Journal:  Antioxid Redox Signal       Date:  2010-10-30       Impact factor: 8.401

3.  A meta-analysis of oxidative stress markers in schizophrenia.

Authors:  Ming Zhang; ZhongMing Zhao; Lin He; ChunLing Wan
Journal:  Sci China Life Sci       Date:  2010-02-12       Impact factor: 6.038

4.  Putrescine produces antidepressant-like effects in the forced swimming test and in the tail suspension test in mice.

Authors:  Andrea D E Zomkowski; Adair Roberto S Santos; Ana Lúcia S Rodrigues
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-07-05       Impact factor: 5.067

5.  Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene.

Authors:  Mirjana Tosic; Jurg Ott; Sandra Barral; Pierre Bovet; Patricia Deppen; Fulvia Gheorghita; Marie-Louise Matthey; Josef Parnas; Martin Preisig; Michael Saraga; Alessandra Solida; Sally Timm; August G Wang; Thomas Werge; Michel Cuénod; Kim Quang Do
Journal:  Am J Hum Genet       Date:  2006-07-31       Impact factor: 11.025

6.  Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia.

Authors:  Meena Arvindakshan; Madhav Ghate; Prabhakar K Ranjekar; Denise R Evans; Sahebarao P Mahadik
Journal:  Schizophr Res       Date:  2003-08-01       Impact factor: 4.939

7.  Emotional reactivity to daily life stress in psychosis and affective disorder: an experience sampling study.

Authors:  I Myin-Germeys; F Peeters; R Havermans; N A Nicolson; M W DeVries; P Delespaul; J Van Os
Journal:  Acta Psychiatr Scand       Date:  2003-02       Impact factor: 6.392

8.  Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.

Authors:  Nancy C Andreasen; Marcus Pressler; Peg Nopoulos; Del Miller; Beng-Choon Ho
Journal:  Biol Psychiatry       Date:  2009-11-07       Impact factor: 13.382

Review 9.  The brain dopaminergic system. Pharmacological, behavioural and electrophysiological studies.

Authors:  B Y Glenthøj
Journal:  Dan Med Bull       Date:  1995-02

Review 10.  Primary skin fibroblasts as a model of Parkinson's disease.

Authors:  Georg Auburger; Michael Klinkenberg; Jessica Drost; Katrin Marcus; Blas Morales-Gordo; Wolfram S Kunz; Ulrich Brandt; Vania Broccoli; Heinz Reichmann; Suzana Gispert; Marina Jendrach
Journal:  Mol Neurobiol       Date:  2012-02-19       Impact factor: 5.590

View more
  18 in total

1.  Increased extracellular clusterin in the prefrontal cortex in schizophrenia.

Authors:  Katina M Athanas; Sarah L Mauney; Tsung-Ung W Woo
Journal:  Schizophr Res       Date:  2015-10-21       Impact factor: 4.939

Review 2.  How can studies of resting-state functional connectivity help us understand psychosis as a disorder of brain development?

Authors:  Theodore D Satterthwaite; Justin T Baker
Journal:  Curr Opin Neurobiol       Date:  2014-10-30       Impact factor: 6.627

3.  Oxidative/Nitrosative stress in psychiatric disorders: are we there yet?

Authors:  Patricio O'Donnell; Kim Q Do; Celso Arango
Journal:  Schizophr Bull       Date:  2014-04-08       Impact factor: 9.306

Review 4.  Human dermal fibroblasts in psychiatry research.

Authors:  S Kálmán; K A Garbett; Z Janka; K Mirnics
Journal:  Neuroscience       Date:  2016-02-09       Impact factor: 3.590

5.  Brain bioenergetics and redox state measured by 31P magnetic resonance spectroscopy in unaffected siblings of patients with psychotic disorders.

Authors:  Virginie-Anne Chouinard; Sang-Young Kim; Linda Valeri; Cagri Yuksel; Kyle P Ryan; Guy Chouinard; Bruce M Cohen; Fei Du; Dost Öngür
Journal:  Schizophr Res       Date:  2017-03-01       Impact factor: 4.939

6.  Neuronal copper homeostasis susceptibility by genetic defects in dysbindin, a schizophrenia susceptibility factor.

Authors:  Avanti Gokhale; Alysia Vrailas-Mortimer; Jennifer Larimore; Heather S Comstra; Stephanie A Zlatic; Erica Werner; Daniel F Manvich; P Michael Iuvone; David Weinshenker; Victor Faundez
Journal:  Hum Mol Genet       Date:  2015-07-21       Impact factor: 6.150

7.  Redox Dysregulation in Schizophrenia Revealed by in vivo NAD+/NADH Measurement.

Authors:  Sang-Young Kim; Bruce M Cohen; Xi Chen; Scott E Lukas; Ann K Shinn; A Cagri Yuksel; Tao Li; Fei Du; Dost Öngür
Journal:  Schizophr Bull       Date:  2016-09-24       Impact factor: 9.306

Review 8.  Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology?

Authors:  P Steullet; J H Cabungcal; A Monin; D Dwir; P O'Donnell; M Cuenod; K Q Do
Journal:  Schizophr Res       Date:  2014-07-05       Impact factor: 4.939

9.  Differentiation of oligodendrocyte precursors is impaired in the prefrontal cortex in schizophrenia.

Authors:  Sarah A Mauney; Charmaine Y Pietersen; Kai-C Sonntag; Tsung-Ung W Woo
Journal:  Schizophr Res       Date:  2015-11-14       Impact factor: 4.939

10.  Glutamatergic metabolites among adolescents at risk for psychosis.

Authors:  Caroline Demro; Laura Rowland; S Andrea Wijtenburg; James Waltz; James Gold; Emily Kline; Elizabeth Thompson; Gloria Reeves; L Elliot Hong; Jason Schiffman
Journal:  Psychiatry Res       Date:  2017-07-24       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.